Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20118 Phase 1 in Healthy Adults and Plaque Psoriasis
NCT06846710Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing HS-20118 with Placebo (2 arms). Primary endpoints: Adverse Events at Day 71, Number of participants with abnormalities of physical examination at Day 71 and 3 more. Started May 2025; status: completed.
02
Drugs
HS-20118
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06846710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846710.